Back to top Open menu arrow

Save Save

Cite Cite

Reprints
Sections
No sections available
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Information from Industry June 30, 2020

SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression

https://www.psychiatrist.com/esketamine-ciii-nasal-spray-treatment-resistant-depression/

SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression

 

Save Save

Cite Cite

Vol 86 • 2025 • Number 1

Read the Current Issue

Original Research

Psychological Support in Psychedelic Therapy

Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

Original Research

Suicidal Behaviors and Obstructive Sleep Apnea

Editorial

A Collaborative Endeavor

Brief Report

Sex Differences in PTSD among US Military Veterans

Clinical and Practical Psychopharmacology

Cannabis Use During Pregnancy and Neuropsychiatric Adverse Outcomes in Children and Young Adults
View current Issue

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe